Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial studies the side effects and best dose of pembrolizumab when given
together with afatinib dimaleate in treating patients with non-small cell lung cancer that
has spread to other places in the body and usually cannot be cured or controlled with
treatment, or has come back and does not respond to erlotinib hydrochloride. Monoclonal
antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and
spread. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving pembrolizumab and afatinib dimaleate together may be an
effective treatment for non-small cell lung cancer.